NASDAQ: GNPXGenprex Inc Stock
$1.05+0.01 (+0.96%)
Updated Dec 9, 2024
GNPX Price
$1.05
Fair Value Price
N/A
Market Cap
$8.93M
52 Week Low
$0.28
52 Week High
$14.40
P/E
-0.09x
P/B
5.37x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$22.71M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
1.35
Operating Cash Flow
-$18M
Beta
1.45
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
GNPX Overview
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine GNPX's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
F
Value
C
Growth
F
Momentum
C
Sentiment
D
Safety
F
Financials
F
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
GNPX
Ranked#345 of 556
Ranked#345 of 556
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $23.16 | A | |
| $6.60 | A | |
| $120.80 | A |
Be the first to know about important GNPX news, forecast changes, insider trades & much more!
GNPX News
Overview
Due Diligence Score
–
Industry Average (22)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how GNPX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
GNPX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
GNPX is good value based on its book value relative to its share price (5.37x), compared to the US Biotechnology industry average (5.68x)
P/B vs Industry Valuation
GNPX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more GNPX due diligence checks available for Premium users.
Valuation
GNPX fair value
Fair Value of GNPX stock based on Discounted Cash Flow (DCF)
Price
$1.05
Fair Value
$4.93
Undervalued by
78.68%
GNPX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
GNPX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.09x
Industry
-107.81x
Market
29.44x
GNPX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
5.37x
Industry
5.68x
GNPX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
GNPX's financial health
Profit margin
Revenue
$0.0
Net Income
-$4.3M
Profit Margin
0%
GNPX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$3.9M
Liabilities
$2.2M
Debt to equity
1.35
GNPX's short-term liabilities ($2.24M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
GNPX's short-term assets ($1.92M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
GNPX's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
GNPX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.2M
Investing
$0.0
Financing
$1.2M
GNPX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
GNPX vs Biotech Stocks
Genprex Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.